Cytokinetics To Move On From Omecamtiv After FDA’s Complete Response Letter

Company said it will not conduct the additional Phase III trial recommended by the US FDA. Instead, it will focus on its cardiac myosin inhibitor, aficamten, and look for partners to take omecamtiv forward.